NUXIPIM Injection contains Cefepime,

A fourth-generation cephalosporin antibiotic available in 500mg and 1g strengths for intravenous (IV) or intramuscular (IM) administration. The attached packaging identifies NUXIPIM as Cefepime Injection and shows both 500mg and 1g presentations. Bosch Pharmaceuticals lists NUXIPIM 500mg and NUXIPIM 1000mg as injectable Cefepime products and specifies Cefepime hydrochloride with sterile arginine Cefepime injection is a broad-spectrum, bactericidal antibiotic used for the treatment of susceptible bacterial infections, including certain respiratory tract, urinary tract, skin and soft-tissue infections and other serious infections as determined by a healthcare professional. The choice between NUXIPIM 500mg and NUXIPIM 1g depends on factors such as the type and severity of infection, age, body weight and kidney function. Cefepime is a prescription antibiotic and should be administered only according to a qualified healthcare professional’s instructions.

Available Strengths

The manufacturer specifies separate solvent volumes for the 500mg and 1g presentations.

Key Benefits

• Contains Cefepime, a fourth-generation cephalosporin antibiotic.
• Available in convenient 500mg and 1g injection strengths.
• Provides broad-spectrum antibacterial activity against susceptible Gram-positive and Gram-negative bacteria.
• Can be administered by IV or IM route, depending on the clinical situation.
• Used in hospital and clinical settings for susceptible bacterial infections.
• The 1g presentation may be selected for infections requiring a higher prescribed dose.
• Manufactured by Bosch Pharmaceuticals (Pvt.) Ltd., Pakistan.

How It Works

Cefepime is a bactericidal beta-lactam antibiotic. It works by interfering with bacterial cell-wall synthesis, ultimately causing susceptible bacteria to die. Cefepime has activity against a broad range of Gram-positive and Gram-negative organisms and is classified pharmacologically as a fourth-generation cephalosporin.

Directions for Use

NUXIPIM should be reconstituted and administered by a qualified healthcare professional. It may be administered by intravenous injection, intravenous infusion or intramuscular injection according to the prescribed regimen and clinical requirements.

The prescribed dose depends on the infection being treated, its severity, the patient’s age and weight, and kidney function. Patients with renal impairment generally require dosage adjustment because cefepime is primarily eliminated through the kidneys.

For the manufacturer’s presentations, the stated reconstitution volumes include 5mL solvent for the 500mg IV presentation and 10mL for the 1g IV presentation. The product information also provides separate volumes for IM administration. Preparation should always follow the approved prescribing information and healthcare-facility procedures.

Do not self-administer NUXIPIM Injection.

Uses / Therapeutic Applications

NUXIPIM (Cefepime) may be prescribed for susceptible bacterial infections, including:

• Mild to moderate urinary tract infections.
• Other susceptible mild to moderate bacterial infections.
• Serious bacterial infections requiring parenteral antibiotic therapy.
• Certain respiratory tract infections.
• Infections caused by susceptible Gram-positive and Gram-negative organisms.
• Infections involving organisms such as Pseudomonas aeruginosa, when clinically appropriate and susceptible.

The exact indication should be determined by the treating healthcare professional based on the patient’s condition and microbiological information when available.

Precautions

• NUXIPIM is a prescription antibiotic and should only be used under medical supervision.
• Do not use in patients with a known immediate hypersensitivity to Cefepime, cephalosporins or other beta-lactam antibiotics.
• Tell your doctor about previous serious allergies to penicillins, cephalosporins or other antibiotics.
• Patients with kidney impairment may require dosage adjustment.
• Cefepime may cause neurological adverse effects, particularly when inappropriate doses are used in patients with renal impairment.
• Inform your doctor about all medicines you are taking before receiving Cefepime.
• Antibiotics should not be used to treat viral infections such as ordinary colds or influenza.
• Complete the prescribed treatment course unless your healthcare professional specifically advises otherwise.
• During pregnancy or breastfeeding, use only when considered necessary by a healthcare professional.

Possible Side Effects

Possible adverse effects associated with Cefepime may include injection-site reactions, diarrhea, nausea, vomiting, headache, rash and gastrointestinal discomfort. Less common but potentially serious reactions include severe allergic reactions and neurological effects such as confusion, hallucinations, encephalopathy, myoclonus or seizures, particularly in patients with renal impairment or excessive exposure.

Seek urgent medical attention if severe allergic symptoms, difficulty breathing, facial swelling, severe skin reactions, seizures or significant changes in consciousness occur.

Drug Interactions

Tell your healthcare professional about all medicines you are receiving. The manufacturer’s prescribing information notes physical-chemical incompatibilities with certain injectable medicines, including metronidazole, vancomycin, gentamicin, tobramycin, netilmicin and aminophylline, meaning they should not be mixed or administered through the same IV route without appropriate compatibility management.

Storage Instructions

• Store the dry powder below 25°C, according to the manufacturer’s instructions.
• Protect from heat, sunlight and moisture.
• Keep the vial in its original packaging until required.
• Keep out of reach of children.
• Reconstituted solutions should be handled according to the manufacturer’s stability and healthcare-facility requirements.
• Inspect the prepared solution before administration and do not use if visible particles are present.
• The vial is intended for single use and remaining reconstituted solution should be discarded according to appropriate procedures.

Manufacturer Information

Brand: NUXIPIM
Generic Name: Cefepime
Manufacturer: Bosch Pharmaceuticals (Pvt.) Ltd.
Country: Pakistan
Therapeutic Segment: Antibiotic / Cephalosporin
Pharmacological Class: Fourth-Generation Cephalosporin
Available Strengths: 500mg and 1g
Routes: IV / IM

Bosch Pharmaceuticals’ official product information confirms NUXIPIM as a Cefepime antibiotic and lists both 500mg and 1000mg injection presentations.

Product Specifications